Dual D-2 dopamine receptor and beta(2)-adrenoceptor agonists for the modulation of sensory nerves in COPD

Viozan(TM) is a first in class dual D-2 dopamine receptor and beta (2)-adre noceptor agonist. Preclinical studies have demonstrated that activation of D-2-receptors inhibits sensory afferent driven processes including cough, m ucus production and tachypnoea. Clinical studies in COPD patients have show n that Viozan significantly improves the symptoms of cough, breathlessness, sputum production and health status quality of life. The combination of D- 2-receptor agonist activity to modulate sensory nerve reflexes with beta (2 )-adrenoceptor agonist activity to provide bronchodilatation is a novel app roach to the management of COPD.